JP2022535924A5 - - Google Patents
Info
- Publication number
- JP2022535924A5 JP2022535924A5 JP2021572583A JP2021572583A JP2022535924A5 JP 2022535924 A5 JP2022535924 A5 JP 2022535924A5 JP 2021572583 A JP2021572583 A JP 2021572583A JP 2021572583 A JP2021572583 A JP 2021572583A JP 2022535924 A5 JP2022535924 A5 JP 2022535924A5
- Authority
- JP
- Japan
- Prior art keywords
- complex according
- polypeptide complex
- seq
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025050785A JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858254P | 2019-06-06 | 2019-06-06 | |
| US62/858,254 | 2019-06-06 | ||
| US202062978662P | 2020-02-19 | 2020-02-19 | |
| US62/978,662 | 2020-02-19 | ||
| PCT/US2020/036493 WO2020247871A2 (en) | 2019-06-06 | 2020-06-05 | Compositions and methods relating to tumor activated t cell engagers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050785A Division JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535924A JP2022535924A (ja) | 2022-08-10 |
| JP2022535924A5 true JP2022535924A5 (enExample) | 2023-06-09 |
Family
ID=73652312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572583A Pending JP2022535924A (ja) | 2019-06-06 | 2020-06-05 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
| JP2025050785A Pending JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050785A Pending JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20230220105A1 (enExample) |
| EP (1) | EP3980131A4 (enExample) |
| JP (2) | JP2022535924A (enExample) |
| KR (1) | KR20220052898A (enExample) |
| CN (1) | CN114423499A (enExample) |
| WO (2) | WO2020247867A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210115106A1 (en) * | 2017-12-07 | 2021-04-22 | Janux Therapeutics, Inc. | Modified t cell receptors |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| MX2023013382A (es) | 2020-04-04 | 2024-01-30 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| EP4631977A3 (en) | 2020-08-11 | 2025-12-10 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| CN114656562B (zh) * | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| US20240254241A1 (en) * | 2021-05-11 | 2024-08-01 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| CN119451993A (zh) * | 2022-05-04 | 2025-02-14 | 佳努克斯治疗公司 | 用于靶向cd28和pd-l1的肿瘤激活多特异性抗体及其使用方法 |
| IL318933A (en) * | 2022-08-18 | 2025-04-01 | Immunocore Ltd | Multi-functional binding molecules |
| AU2024266051A1 (en) * | 2023-05-03 | 2025-11-20 | Janux Therapeutics, Inc. | Tumor activated antibodies targeting cd3 and uses thereof |
| WO2025085855A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| WO2025085862A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| GB2641580A (en) * | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031264A1 (en) * | 1996-01-25 | 2001-10-18 | Andrew Segal | Vaccine compositions and methods of modulating immune responses |
| CA2654794A1 (en) * | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US20110214199A1 (en) * | 2007-06-06 | 2011-09-01 | Monsanto Technology Llc | Genes and uses for plant enhancement |
| US20090148905A1 (en) * | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| WO2013041865A1 (en) * | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
| CN110078827A (zh) * | 2012-04-27 | 2019-08-02 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| US9562110B2 (en) * | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| US9562073B2 (en) * | 2014-01-31 | 2017-02-07 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN107709356A (zh) * | 2015-06-26 | 2018-02-16 | 南加利福尼亚大学 | 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞 |
| KR20180133442A (ko) * | 2016-04-13 | 2018-12-14 | 비비아 바이오테크 에스.엘. | 생체외 bite 활성화된 t 세포 |
| EP3493844A4 (en) * | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| EP3694885A1 (en) * | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| BR112020023330A2 (pt) * | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
-
2020
- 2020-06-05 JP JP2021572583A patent/JP2022535924A/ja active Pending
- 2020-06-05 US US17/616,278 patent/US20230220105A1/en active Pending
- 2020-06-05 US US17/616,281 patent/US20230220109A1/en active Pending
- 2020-06-05 KR KR1020227000224A patent/KR20220052898A/ko active Pending
- 2020-06-05 CN CN202080056153.1A patent/CN114423499A/zh active Pending
- 2020-06-05 EP EP20819457.1A patent/EP3980131A4/en active Pending
- 2020-06-05 WO PCT/US2020/036489 patent/WO2020247867A2/en not_active Ceased
- 2020-06-05 WO PCT/US2020/036493 patent/WO2020247871A2/en not_active Ceased
-
2024
- 2024-07-26 US US18/785,900 patent/US20240376226A1/en not_active Abandoned
-
2025
- 2025-03-25 JP JP2025050785A patent/JP2025111446A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535924A5 (enExample) | ||
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP2024532485A5 (enExample) | ||
| JP2021503455A5 (enExample) | ||
| JP7600327B2 (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| EP2050764A1 (en) | Novel polyvalent bispecific antibody format and uses thereof | |
| JP2021510521A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2013515508A5 (enExample) | ||
| JP2023548443A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2017514515A5 (enExample) | ||
| JP2019502694A5 (enExample) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2021508707A5 (enExample) | ||
| FI3765525T3 (fi) | Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä | |
| JP2020533004A5 (enExample) | ||
| JP2023552462A5 (enExample) | ||
| JP2021515793A5 (enExample) | ||
| JP2021512151A5 (enExample) | ||
| JP2022504826A5 (enExample) | ||
| JP2023511963A5 (enExample) | ||
| JP2022538222A5 (enExample) | ||
| JP2022542574A5 (enExample) | ||
| JP2022513050A5 (enExample) |